Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.36 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119807 | 0.88 | DHODH (0.44) | CMKLR1DHODH | |
| SCHEMBL15540397 | 0.87 | CMKLR1 (0.48) | AGTR2LTB4R2CMKLR1 | |
| SCHEMBL844427 | 0.84 | ABCB11 (0.38) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL9494117 | 0.80 | KDM4E (0.38) | — | |
| SCHEMBL3821755 | 0.79 | AGTR2 (0.45) | AGTR1PPARGAGTR2LTB4R2CMKLR1 | |
| SCHEMBL5746358 | 0.79 | PPARG (0.34) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL3638790 | 0.77 | AGTR1 (0.39) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL8836872 | 0.76 | BRS3 (0.33) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL9291479 | 0.76 | PARP1 (0.35) | ABCB11EGFRERBB2CYP3A4ADORA3 | |
| SCHEMBL9491699 | 0.76 | LMNA (0.35) | CMKLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432996-B1 | ADMINISTERING BENZIMIDAZOLE DERIVATIVE ANGIOTENSIN II ANTAGONIST, INDANE DERIVATIVE ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AND PYRIDINE DERIVATIVE HMG-CO A REDUCTASE INHIBITOR TO TREAT PROSTPRANDIAL HYPERGLYCEMIA IN DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-13 | — | — | US | claimed |
| EP-0914158-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 1999-05-12 | — | — | EP | claimed |
| WO-1997037688-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | claimed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-20200283480-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | BAUSCH HEALTH COMPANIES INC. (CA) | 2020-09-10 | — | — | US | disclosed |
| EP-3065757-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | Synergy Pharmaceuticals Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3004138-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Synergy Pharmaceuticals Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2970384-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | Synergy Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2825188-A1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Synergy Pharmaceuticals Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| WO-2009149279-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2008151257-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008002971-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1306088-B1 | Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic | TAKEDA PHARMACEUTICAL (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20040219208-A1 | Sustained-release medicines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1452176-A1 | INSULIN RESISTANCE IMPROVING AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| EP-0914158-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 1999-05-12 | — | — | EP | disclosed |
| WO-1997037688-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | disclosed |
| US-5354766-A | 2-Ethoxy-1-((2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl)methyl)benzimidazole-7-carboxylic acid; hypotensive agents; CNS activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219208-A1 | Sustained-release medicines | ACE, AGTR2, AGT | ABCB11 290/4885EGFR 2159/4885ERBB2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.